FY2024 Earnings Forecast for Geron Issued By Leerink Partnrs

Geron Co. (NASDAQ:GERN) – Investment analysts at Leerink Partnrs decreased their FY2024 earnings per share (EPS) estimates for shares of Geron in a report issued on Monday, January 6th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will post earnings per share of ($0.29) for the year, down from their previous forecast of ($0.28). The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron’s Q4 2024 earnings at ($0.06) EPS, Q1 2025 earnings at ($0.03) EPS, FY2025 earnings at $0.00 EPS and FY2026 earnings at $0.19 EPS.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The business had revenue of $28.27 million during the quarter, compared to analysts’ expectations of $18.97 million. During the same quarter in the previous year, the company earned ($0.08) EPS. The business’s revenue was up 17138.4% on a year-over-year basis.

GERN has been the subject of a number of other reports. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of Geron in a research report on Friday, December 13th. Barclays raised shares of Geron to a “strong-buy” rating in a research report on Friday, November 29th. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Geron in a report on Tuesday, December 10th. Finally, Scotiabank started coverage on shares of Geron in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Geron currently has an average rating of “Moderate Buy” and a consensus target price of $7.15.

Geron Trading Up 0.6 %

Shares of GERN stock opened at $3.42 on Wednesday. The stock has a market cap of $2.07 billion, a P/E ratio of -10.69 and a beta of 0.55. Geron has a 1 year low of $1.64 and a 1 year high of $5.34. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The stock has a 50 day simple moving average of $3.84 and a 200 day simple moving average of $4.24.

Hedge Funds Weigh In On Geron

A number of institutional investors and hedge funds have recently bought and sold shares of the company. National Bank of Canada FI grew its holdings in Geron by 1,200.0% during the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 6,000 shares during the last quarter. Readystate Asset Management LP acquired a new stake in Geron in the third quarter valued at $58,000. Rovin Capital UT ADV acquired a new position in Geron during the 3rd quarter worth about $62,000. CIBC Asset Management Inc grew its position in shares of Geron by 32.7% in the 2nd quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 3,805 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in Geron during the third quarter worth $67,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.